Hims & Hers Health (NYSE:HIMS) Price Target Raised to $27.00

Hims & Hers Health (NYSE:HIMS) had its price target lifted by Truist Financial from $23.00 to $27.00 in a research note released on Friday morning,Benzinga reports. They currently have a hold rating on the stock.

A number of other research firms have also recently weighed in on HIMS. Weiss Ratings cut Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a report on Tuesday, May 12th. TD Cowen cut their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $25.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $31.43.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $28.10 on Friday. The business’s 50-day simple moving average is $30.75 and its 200-day simple moving average is $26.28. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $70.43. The firm has a market cap of $6.50 billion, a price-to-earnings ratio of -312.26, a P/E/G ratio of 79.05 and a beta of 2.35.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same quarter last year, the firm posted $0.20 earnings per share. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. As a group, equities research analysts expect that Hims & Hers Health will post 0.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 18,197 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $34.03, for a total value of $619,243.91. Following the sale, the chief financial officer owned 284,321 shares in the company, valued at $9,675,443.63. This represents a 6.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the sale, the insider owned 181,861 shares of the company’s stock, valued at approximately $6,365,135. This represents a 11.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 83,126 shares of company stock worth $2,711,339 over the last three months. Insiders own 11.76% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently bought and sold shares of HIMS. Versant Capital Management Inc raised its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares in the last quarter. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health during the 4th quarter valued at about $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health during the third quarter worth approximately $28,000. Finally, Bogart Wealth LLC lifted its stake in Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The FDA panel’s favorable peptide recommendation could eventually broaden Hims & Hers’ addressable market and support its emerging peptide therapy business. FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight
• Neutral Sentiment: Truist raised its price target on HIMS to $27 from $23, but kept a hold rating, suggesting the firm sees limited upside from current levels. Tickerreport.com
• Neutral Sentiment: Recent commentary and search interest have kept HIMS in focus, reflecting elevated trading attention around the FDA-driven peptide story. Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
• Negative Sentiment: The sharp pullback appears consistent with a sell-the-news move as traders locked in gains after the initial FDA-related spike, since the regulatory process is not finished. Why Is HIMS Stock Rallying 13% Today?
• Negative Sentiment: Insider selling and mixed hedge fund positioning may also weigh on investor sentiment, as many major holders reduced exposure in the latest quarter. Hims & Hers Health Slides as Traders Fade Peptide Rally

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.